drugset / Trial / NCT02477540

A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia

NCT02477540

Phase 1 Withdrawn Pharmicell Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial to study the Safety and Efficacy of Autologous Mesenchymal stem cells in critical limb ischemia.

Timeline

Start
2019-12
Primary completion
2020-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous bone marrow-derived mesenchymal stem cells Cell therapy 5e+07 cells Intramuscular

Indications